Skip to content

Study · Animal study (in vivo) · mouse · 2022

10 results

Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.

Al-Onaizi MA, Thériault P, Lecordier S, Prefontaine P, Rivest S, ElAli A

Brain, behavior, and immunity31 Jul 2021Cited by 15 (Europe PMC)

PMID34343617 (opens in a new tab)DOI10.1016/j.bbi.2021.07.016 (opens in a new tab)PepBankPUB-34343617
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In young APP/PS1 mice, early ARA‑290 treatment decelerated progression of Aβ pathology.

    In plain wordsIn young mice with Alzheimer-like disease, early ARA‑290 slowed the build-up of amyloid-β.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseAβ pathology progression
    Study

    mousen: not reported in source

    Young APP/PS1 mice (early-onset AD model)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Our findings indicate that ARA 290 early treatment decelerated Aβ pathology progression in APP/PS1 mice while improving cognitive functions.
    1 context sentence
    Summary · context
    We first evaluated the effects of early systemic ARA 290 administration on AD-like pathology in an early-onset model, represented by young APP/PS1 mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In young APP/PS1 mice, early ARA‑290 treatment improved cognitive functions.

    In plain wordsIn young mice with Alzheimer-like disease, early ARA‑290 improved thinking and memory tests.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseCognitive function
    Study

    mousen: not reported in source

    Young APP/PS1 mice (early-onset AD model)
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Our findings indicate that ARA 290 early treatment decelerated Aβ pathology progression in APP/PS1 mice while improving cognitive functions.
    1 context sentence
    Summary · context
    We first evaluated the effects of early systemic ARA 290 administration on AD-like pathology in an early-onset model, represented by young APP/PS1 mice.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In young APP/PS1 mice, ARA‑290 potently increased total monocyte levels.

    In plain wordsIn young mice with Alzheimer-like disease, ARA‑290 raised the number of monocytes, a type of immune cell.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseTotal monocyte level
    Study

    mousen: not reported in source

    Young APP/PS1 mice (early-onset AD model)
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    ARA 290 potently increased the levels of total monocytes by specifically stimulating the generation of Ly6CLow patrolling subset
    1 context sentence
    Summary · context
    We first evaluated the effects of early systemic ARA 290 administration on AD-like pathology in an early-onset model, represented by young APP/PS1 mice.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In young APP/PS1 mice, ARA‑290 increased the generation of the Ly6C-low patrolling monocyte subset.

    In plain wordsIn young mice with Alzheimer-like disease, ARA‑290 raised a type of monocyte that helps clear amyloid-β.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseLy6C-low patrolling monocyte generation
    Study

    mousen: not reported in source

    Young APP/PS1 mice (early-onset AD model)
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    ARA 290 potently increased the levels of total monocytes by specifically stimulating the generation of Ly6CLow patrolling subset, which are implicated in clearing Aβ from the cerebral vasculature
    1 context sentence
    Summary · context
    We first evaluated the effects of early systemic ARA 290 administration on AD-like pathology in an early-onset model, represented by young APP/PS1 mice.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In young APP/PS1 mice, ARA‑290 reduced overall Aβ burden in the brain.

    In plain wordsIn young mice with Alzheimer-like disease, ARA‑290 reduced the amount of amyloid-β in the brain.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseBrain Aβ burden
    Study

    mousen: not reported in source

    Young APP/PS1 mice (early-onset AD model)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    and subsequently reducing overall Aβ burden in the brain.
    1 context sentence
    Summary · context
    We first evaluated the effects of early systemic ARA 290 administration on AD-like pathology in an early-onset model, represented by young APP/PS1 mice.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In young APP/PS1 mice, ARA‑290 increased the levels of monocyte progenitors in the bone marrow.

    In plain wordsIn young mice with Alzheimer-like disease, ARA‑290 raised monocyte precursor cells in the bone marrow.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseBone marrow monocyte progenitors
    Study

    mousen: not reported in source

    Young APP/PS1 mice (early-onset AD model)
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Moreover, ARA 290 increased the levels of monocyte progenitors in the bone marrow.
    1 context sentence
    Summary · context
    We first evaluated the effects of early systemic ARA 290 administration on AD-like pathology in an early-onset model, represented by young APP/PS1 mice.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In chimeric young APP/PS1 mice lacking Ly6C-low patrolling monocytes, ARA‑290 was inefficient in attenuating Aβ pathology.

    In plain wordsIn young Alzheimer-model mice lacking patrolling monocytes, ARA‑290 did not reduce amyloid-β pathology.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    No significant changeAβ pathology with patrolling monocytes depleted
    Study

    mousen: not reported in source

    Chimeric young APP/PS1 mice with Ly6C-low patrolling monocytes depleted
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Using chimeric APP/PS1 mice in which Ly6CLow patrolling subset are selectively depleted, ARA 290 was inefficient in attenuating Aβ pathology and ameliorating cognitive functions in young animals.
    1 context sentence
    Summary · context
    We first evaluated the effects of early systemic ARA 290 administration on AD-like pathology in an early-onset model, represented by young APP/PS1 mice.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In chimeric young APP/PS1 mice lacking Ly6C-low patrolling monocytes, ARA‑290 was inefficient in ameliorating cognitive functions.

    In plain wordsIn young Alzheimer-model mice lacking patrolling monocytes, ARA‑290 did not improve cognition.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    No significant changeCognition with patrolling monocytes depleted
    Study

    mousen: not reported in source

    Chimeric young APP/PS1 mice with Ly6C-low patrolling monocytes depleted
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Using chimeric APP/PS1 mice in which Ly6CLow patrolling subset are selectively depleted, ARA 290 was inefficient in attenuating Aβ pathology and ameliorating cognitive functions in young animals.
    1 context sentence
    Summary · context
    We first evaluated the effects of early systemic ARA 290 administration on AD-like pathology in an early-onset model, represented by young APP/PS1 mice.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In aged APP/PS1 mice with advanced pathology, ARA‑290 failed to reverse Aβ pathology.

    In plain wordsIn old Alzheimer-model mice, ARA‑290 did not reverse amyloid-β pathology.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    No significant changeAβ pathology in aged mice
    Study

    mousen: not reported in source

    Aged APP/PS1 mice (late-onset AD model)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    In aged APP/PS1 mice in which AD-like pathology is at advanced stages, ARA 290 failed to reverse Aβ pathology and to increase the levels of circulating monocytes.
    1 context sentence
    Summary · context
    We first evaluated the effects of early systemic ARA 290 administration on AD-like pathology in an early-onset model, represented by young APP/PS1 mice.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In aged APP/PS1 mice with advanced pathology, ARA‑290 failed to increase circulating monocytes.

    In plain wordsIn old Alzheimer-model mice, ARA‑290 did not raise circulating monocyte numbers.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    No significant changeCirculating monocytes in aged mice
    Study

    mousen: not reported in source

    Aged APP/PS1 mice (late-onset AD model)
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    In aged APP/PS1 mice in which AD-like pathology is at advanced stages, ARA 290 failed to reverse Aβ pathology and to increase the levels of circulating monocytes.
    1 context sentence
    Summary · context
    We first evaluated the effects of early systemic ARA 290 administration on AD-like pathology in an early-onset model, represented by young APP/PS1 mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.